<DOC>
	<DOCNO>NCT01070823</DOCNO>
	<brief_summary>The primary objective define prevalence serum anti-JCV antibody relapse multiple sclerosis ( MS ) participant receive Tysabri® ( natalizumab ) consider treatment . Secondary objective analytically validate anti-JCV antibody assay plasma matrix determine change anti-JCV antibody status time .</brief_summary>
	<brief_title>JC-Virus ( JCV ) Antibody Program</brief_title>
	<detailed_description>This study require serum , plasma urine collection enrollment every 6 month thereafter two year .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Relapsing multiple sclerosis ( MS ) patient interested consider begin treatment Tysabri® ( natalizumab ) . Key Patients participate Tysabri® ( natalizumab ) clinical trial study sponsor Biogen Idec Elan may participate study . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sample Collection</keyword>
	<keyword>JCV</keyword>
	<keyword>PML</keyword>
</DOC>